As the first precision pilot in Autism, COUNT aims to advance the understanding of Autism Spectrum Disorder (ASD) via a novel, tech-enabled longitudinal approach, with the ultimate goal of managing and treating the disorder at the individual level.
Interested in funding this study? Contact Us >
ABOUT THE PROGRAM
COUNT’s precision approach will leverage deep individual profiling, combining genomic, proteomic, metabolomic, lipidomic, and physiological profiles of an individual patient over a 12-month period.
The first stage of this project is a pilot study which will include 100 participants and 50 controls. After the pilot study, Stanford and COUNT partners plan to expand this program to include 10,000 people with ASD.
U.S Autism Diagnosis in 2020
1 in 54 Children
Autism, a chronic and heterogeneous spectrum disorder with many life-altering symptoms and comorbidities, is poorly understood.
Diagnosis is commonly accompanied by other serious conditions like epilepsy, gastrointestinal disturbances, and motor issues. Patients with the same autism diagnosis experience a wide variety of distinct symptoms, likely due to differences in genes, environment, and lifestyle.
Understand ASD Subtypes & Symptom Predictors
Comorbidities, symptom severity and frequency will be documented regularly over a year, along with physiological and environmental data from wearable devices and deep omics phenotyping.
Identify subtypes of ASD based on data derived from wearables, physiological measurements and subtypes’ relationships with clinically relevant symptoms and omic profiles.
Identify predictors of symptom episodes or exacerbations using wearable data, opening up new opportunities for personalized symptom management.
Longitudinal Multi-Omic Profiling
Patient & Care Team
Improve experience with new tools
This study will provide a much-needed characterization of the heterogeneity of ASD and the physiological correlates of ASD symptoms.
Different types of data collected in the study are visualized and returned to users in real time.
A tested and iterated precision health platform is designed for use by patients and families to manage ASD.
Innovate with high quality data
We want to build and test a precision health autism database for use by the general research community.
The architecture will make longitudinal studies easier to participate in, cheaper to conduct, and more useful for cohort families.
This study will serve as a blueprint for studies of many chronic diseases with similarly complex etiologies, symptoms, and co-existing conditions.
2m Foundation, is a nonprofit organization based in Silicon Valley, driven by the vision to redesign a frictionless and accessible healthcare model. The foundation partners with world-renowned experts in microbiome, immunology and neuroscience to develop technology-enabled initiatives that change the way we define and manage chronic diseases.
Visit 2m >
The Stanford research team is led by Dr. Michael Snyder, Chair of the Genetics Department and the Director at the Center for Genomics and Personalized Medicine at Stanford University. Dr. Snyder has pioneered longitudinal personalized multi-omic profiling, tracking, and integrating millions of pieces of health data over time for an individual.
See Research >